206 related articles for article (PubMed ID: 28191612)
1. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.
Leppänen J; Helminen O; Huhta H; Kauppila JH; Isohookana J; Haapasaari KM; Lehenkari P; Saarnio J; Karttunen TJ
Virchows Arch; 2017 Apr; 470(4):401-410. PubMed ID: 28191612
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 2 and Toll-like receptor 4 predict favorable prognosis in local pancreatic cancer.
Lanki MA; Seppänen HE; Mustonen HK; Böckelman C; Juuti AT; Hagström JK; Haglund CH
Tumour Biol; 2018 Sep; 40(9):1010428318801188. PubMed ID: 30246618
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptors 2, 4 and 9 and hypoxia markers HIF-1alpha and CAIX in pancreatic intraepithelial neoplasia.
Leppänen J; Helminen O; Huhta H; Kauppila JH; Isohookana J; Haapasaari KM; Karihtala P; Parkkila S; Saarnio J; Lehenkari PP; Karttunen TJ
APMIS; 2018 Nov; 126(11):852-863. PubMed ID: 30357962
[TBL] [Abstract][Full Text] [Related]
4. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
5. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer.
Lanki M; Seppänen H; Mustonen H; Hagström J; Haglund C
PLoS One; 2019; 14(7):e0219245. PubMed ID: 31314777
[TBL] [Abstract][Full Text] [Related]
7. Mortalin expression in pancreatic cancer and its clinical and prognostic significance.
Cui X; Li Z; Piao J; Li J; Li L; Lin Z; Jin A
Hum Pathol; 2017 Jun; 64():171-178. PubMed ID: 28412209
[TBL] [Abstract][Full Text] [Related]
8. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.
Kaira K; Sunose Y; Arakawa K; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Takeyoshi I
Histopathology; 2015 Jan; 66(2):234-43. PubMed ID: 24845232
[TBL] [Abstract][Full Text] [Related]
11. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer.
Guo M; Luo G; Liu C; Cheng H; Lu Y; Jin K; Liu Z; Long J; Liu L; Xu J; Huang D; Ni Q; Yu X
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27399694
[TBL] [Abstract][Full Text] [Related]
13. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma.
Hu D; Ansari D; Zhou Q; Sasor A; Said Hilmersson K; Andersson R
World J Surg Oncol; 2019 Feb; 17(1):29. PubMed ID: 30736807
[TBL] [Abstract][Full Text] [Related]
14. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival.
Yu XZ; Guo ZY; Di Y; Yang F; Ouyang Q; Fu DL; Jin C
Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):104-109. PubMed ID: 28119265
[TBL] [Abstract][Full Text] [Related]
15. Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma.
Hu D; Ansari D; Zhou Q; Sasor A; Hilmersson KS; Bauden M; Jiang Y; Andersson R
BMC Cancer; 2018 Nov; 18(1):1096. PubMed ID: 30419838
[TBL] [Abstract][Full Text] [Related]
16. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
17. Podocalyxin Is a Marker of Poor Prognosis in Pancreatic Ductal Adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Fermér C; Nilsson O; Seppänen H; Haglund C
PLoS One; 2015; 10(6):e0129012. PubMed ID: 26053486
[TBL] [Abstract][Full Text] [Related]
18. Mucin expression in endoscopic ultrasound-guided fine-needle aspiration specimens is a useful prognostic factor in pancreatic ductal adenocarcinoma.
Higashi M; Yokoyama S; Yamamoto T; Goto Y; Kitazono I; Hiraki T; Taguchi H; Hashimoto S; Fukukura Y; Koriyama C; Mataki Y; Maemura K; Shinchi H; Jain M; Batra SK; Yonezawa S
Pancreas; 2015 Jul; 44(5):728-34. PubMed ID: 25906442
[TBL] [Abstract][Full Text] [Related]
19. B7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer.
Shen L; Qian Y; Wu W; Weng T; Wang FXC; Hong B; Wu Z; Wang Q; Sang Y; Zhang H; Zhou X; Yao H
Hum Pathol; 2017 Aug; 66():79-85. PubMed ID: 28600225
[TBL] [Abstract][Full Text] [Related]
20. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
